Altered Histone Modifications in Cancer



In human health and disease the choreographed actions of a wide armory of transcription factors govern the regulated expression of coding and nonprotein coding genes. These actions are central to human health and are evidently aberrant in cancer. Central components of regulated gene expression are a variety of epigenetic mechanisms that include histone modifications. The post-translational modifications of histones are widespread and diverse, and appear to be spatial-­temporally regulated in a highly intricate manner. The true functional consequences of these patterns of regulation are still emerging. Correlative evidence supports the idea that these patterns are distorted in malignancy on both a genome-wide and a discrete gene loci level. These patterns of distortion also often reflect the altered expression of the enzymes that control these histone states. Similarly gene expression patterns also appear to reflect a correlation with altered histone modifications at both the candidate loci and genome-wide level. Clarity is emerging in resolving these relationships between histone modification status and gene expression ­patterns. For example, altered transcription factor interactions with the key co-activator and co-repressors, which in turn marshal many of the histone-modifying enzymes, may distort regulation of histone modifications at specific gene loci. In turn these aberrant transcriptional processes can trigger other altered epigenetic events such as DNA methylation and underline the aberrant and specific gene expression patterns in cancer. Considered in this manner, altered expression and recruitment of histone-modifying enzymes may underline the distortion to transcriptional responsiveness observed in malignancy. Insight from understanding these processes addresses the challenge of targeted epigenetic therapies in cancer.



Androgen receptor


Chromatin immunoprecipitation


Co-activator complex




Estrogen receptor alpha


Embryonic stem cell


Histone deacetylase


Jumonji domain containing protein


Jumonji AT-rich interactive domain


Lysine acetyltransferase


Lysine demethylase


Lysine methyltransferase


Lysine-specific demethylase 1


Nuclear co-repressor


Nuclear receptor


Prostate-specific antigen


Su(var), enhancer of zeste and trithorax


Transcription factor


Trichostatin A


Transcription start site


  1. 1.
    Allis CD et al (2007) New nomenclature for chromatin-modifying enzymes. Cell 131: 633–636PubMedGoogle Scholar
  2. 2.
    Turner BM (2005) Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Mol Biol 12:110–112PubMedGoogle Scholar
  3. 3.
    Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251–260PubMedGoogle Scholar
  4. 4.
    Flaus A, Owen-Hughes T (2011) Mechanisms for ATP-dependent chromatin remodelling: the means to the end. FEBS J 278:3579–3595PubMedGoogle Scholar
  5. 5.
    Recouvreux P et al (2011) Linker histones incorporation maintains chromatin fiber plasticity. Biophys J 100:2726–2735PubMedGoogle Scholar
  6. 6.
    Talbert PB, Henikoff S (2010) Histone variants—ancient wrap artists of the epigenome. Nat Rev Mol Cell Biol 11:264–275PubMedGoogle Scholar
  7. 7.
    Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693–705PubMedGoogle Scholar
  8. 8.
    Ngara R, Ndimba R, Borch-Jensen J, Jensen ON, Ndimba B (2012) Identification and profiling of salinity stress-responsive proteins in Sorghum bicolor seedlings. J Proteomics 75: 4139–4150Google Scholar
  9. 9.
    Zhang S, Roche K, Nasheuer HP, Lowndes NF (2011) Modification of histones by sugar beta-N-acetylglucosamine (GlcNAc) occurs on multiple residues, including histone H3 serine 10, and is cell cycle-regulated. J Biol Chem 286:37483–37495PubMedGoogle Scholar
  10. 10.
    Tan M et al (2011) Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146:1016–1028PubMedGoogle Scholar
  11. 11.
    Cosgrove MS (2007) Histone proteomics and the epigenetic regulation of nucleosome mobility. Expert Rev Proteomics 4:465–478PubMedGoogle Scholar
  12. 12.
    Hyland EM et al (2005) Insights into the role of histone H3 and histone H4 core modifiable residues in Saccharomyces cerevisiae. Mol Cell Biol 25:10060–10070PubMedGoogle Scholar
  13. 13.
    Xu F, Zhang K, Grunstein M (2005) Acetylation in histone H3 globular domain regulates gene expression in yeast. Cell 121:375–385PubMedGoogle Scholar
  14. 14.
    Masumoto H, Hawke D, Kobayashi R, Verreault A (2005) A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 436:294–298PubMedGoogle Scholar
  15. 15.
    Vempati RK (2012) DNA damage in the presence of chemical genotoxic agents induce acetylation of H3K56 and H4K16 but not H3K9 in mammalian cells. Mol Biol Rep 39:303–308PubMedGoogle Scholar
  16. 16.
    Clemente-Ruiz M, Gonzalez-Prieto R, Prado F (2011) Histone H3K56 acetylation, CAF1, and Rtt106 coordinate nucleosome assembly and stability of advancing replication forks. PLoS Genet 7:e1002376PubMedGoogle Scholar
  17. 17.
    Watanabe S et al (2010) Structural characterization of H3K56Q nucleosomes and nucleosomal arrays. Biochim Biophys Acta 1799:480–486PubMedGoogle Scholar
  18. 18.
    Xie W et al (2009) Histone h3 lysine 56 acetylation is linked to the core transcriptional network in human embryonic stem cells. Mol Cell 33:417–427PubMedGoogle Scholar
  19. 19.
    Luger K, Richmond TJ (1998) The histone tails of the nucleosome. Curr Opin Genet Dev 8:140–146PubMedGoogle Scholar
  20. 20.
    Ferreira H, Somers J, Webster R, Flaus A, Owen-Hughes T (2007) Histone tails and the H3 alphaN helix regulate nucleosome mobility and stability. Mol Cell Biol 27:4037–4048PubMedGoogle Scholar
  21. 21.
    Lenfant F, Mann RK, Thomsen B, Ling X, Grunstein M (1996) All four core histone N-termini contain sequences required for the repression of basal transcription in yeast. EMBO J 15:3974–3985PubMedGoogle Scholar
  22. 22.
    Ling X, Harkness TA, Schultz MC, Fisher-Adams G, Grunstein M (1996) Yeast histone H3 and H4 amino termini are important for nucleosome assembly in vivo and in vitro: redundant and position-independent functions in assembly but not in gene regulation. Genes Dev 10:686–699PubMedGoogle Scholar
  23. 23.
    Dion MF, Altschuler SJ, Wu LF, Rando OJ (2005) Genomic characterization reveals a simple histone H4 acetylation code. Proc Natl Acad Sci USA 102:5501–5506PubMedGoogle Scholar
  24. 24.
    Turner BM (1993) Decoding the nucleosome. Cell 75:5–8PubMedGoogle Scholar
  25. 25.
    Turner BM, Birley AJ, Lavender J (1992) Histone H4 isoforms acetylated at specific lysine residues define individual chromosomes and chromatin domains in Drosophila polytene nuclei. Cell 69:375–384PubMedGoogle Scholar
  26. 26.
    Kutateladze TG (2011) SnapShot: histone readers. Cell 146:842–842.e1PubMedGoogle Scholar
  27. 27.
    Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ (2007) How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 14:1025–1040PubMedGoogle Scholar
  28. 28.
    Liu Z et al (2010) Jmjd1a demethylase-regulated histone modification is essential for cAMP-response element modulator-regulated gene expression and spermatogenesis. J Biol Chem 285:2758–2770PubMedGoogle Scholar
  29. 29.
    Canzio D et al (2011) Chromodomain-mediated oligomerization of HP1 suggests a nucleosome-bridging mechanism for heterochromatin assembly. Mol Cell 41:67–81PubMedGoogle Scholar
  30. 30.
    Kolasinska-Zwierz P et al (2009) Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet 41:376–381PubMedGoogle Scholar
  31. 31.
    Kourmouli N et al (2004) Heterochromatin and tri-methylated lysine 20 of histone H4 in animals. J Cell Sci 117:2491–2501PubMedGoogle Scholar
  32. 32.
    Ringrose L, Paro R (2007) Polycomb/trithorax response elements and epigenetic memory of cell identity. Development 134:223–232PubMedGoogle Scholar
  33. 33.
    Mateescu B, England P, Halgand F, Yaniv M, Muchardt C (2004) Tethering of HP1 proteins to chromatin is relieved by phosphoacetylation of histone H3. EMBO Rep 5:490–496PubMedGoogle Scholar
  34. 34.
    Ernst J et al (2011) Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473:43–49PubMedGoogle Scholar
  35. 35.
    Kharchenko PV et al (2011) Comprehensive analysis of the chromatin landscape in Drosophila melanogaster. Nature 471:480–485PubMedGoogle Scholar
  36. 36.
    Rada-Iglesias A et al (2011) A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470:279–283PubMedGoogle Scholar
  37. 37.
    Korolev N, Lyubartsev AP, Nordenskiold L (2006) Computer modeling demonstrates that electrostatic attraction of nucleosomal DNA is mediated by histone tails. Biophys J 90: 4305–4316PubMedGoogle Scholar
  38. 38.
    Perico A, La Penna G, Arcesi L (2006) Electrostatic interactions with histone tails may bend linker DNA in chromatin. Biopolymers 81:20–28PubMedGoogle Scholar
  39. 39.
    Takahashi YH et al (2011) Dot1 and histone H3K79 methylation in natural telomeric and HM silencing. Mol Cell 42:118–126PubMedGoogle Scholar
  40. 40.
    Jones B et al (2008) The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet 4:e1000190PubMedGoogle Scholar
  41. 41.
    Lee MG et al (2007) Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318:447–450PubMedGoogle Scholar
  42. 42.
    Agger K et al (2007) UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449:731–734PubMedGoogle Scholar
  43. 43.
    Pekowska A et al (2011) H3K4 tri-methylation provides an epigenetic signature of active enhancers. EMBO J 30:4198–4210PubMedGoogle Scholar
  44. 44.
    Robertson AG et al (2008) Genome-wide relationship between histone H3 lysine 4 mono- and tri-methylation and transcription factor binding. Genome Res 18:1906–1917PubMedGoogle Scholar
  45. 45.
    Zeissig S et al (2007) Butyrate induces intestinal sodium absorption via Sp3-mediated transcriptional up-regulation of epithelial sodium channels. Gastroenterology 132:236–248PubMedGoogle Scholar
  46. 46.
    Augenlicht LH et al (2002) Short chain fatty acids and colon cancer. J Nutr 132: 3804S–3808SPubMedGoogle Scholar
  47. 47.
    Tanaka Y, Bush KK, Klauck TM, Higgins PJ (1989) Enhancement of butyrate-induced differentiation of HT-29 human colon carcinoma cells by 1,25-dihydroxyvitamin D3. Biochem Pharmacol 38:3859–3865PubMedGoogle Scholar
  48. 48.
    Cuezva JM et al (2002) The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 62:6674–6681PubMedGoogle Scholar
  49. 49.
    Racker E, Spector M (1981) Warburg effect revisited: merger of biochemistry and molecular biology. Science 213:303–307PubMedGoogle Scholar
  50. 50.
    Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134:703–707PubMedGoogle Scholar
  51. 51.
    Cavill R et al (2011) Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells. PLoS Comput Biol 7:e1001113PubMedGoogle Scholar
  52. 52.
    Su G, Burant CF, Beecher CW, Athey BD, Meng F (2011) Integrated metabolome and transcriptome analysis of the NCI60 dataset. BMC Bioinformatics 12(Suppl 1):S36PubMedGoogle Scholar
  53. 53.
    Sharon D, Chen R, Snyder M (2010) Systems biology approaches to disease marker discovery. Dis Markers 28:209–224PubMedGoogle Scholar
  54. 54.
    Misteli T, Soutoglou E (2009) The emerging role of nuclear architecture in DNA repair and genome maintenance. Nat Rev Mol Cell Biol 10:243–254PubMedGoogle Scholar
  55. 55.
    Seligson DB et al (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262–1266PubMedGoogle Scholar
  56. 56.
    Kurdistani SK (2007) Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer 97:1–5PubMedGoogle Scholar
  57. 57.
    He LR et al (2009) Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 9:461PubMedGoogle Scholar
  58. 58.
    Tzao C et al (2009) Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 22:252–260PubMedGoogle Scholar
  59. 59.
    Yu J et al (2007) A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67:10657–10663PubMedGoogle Scholar
  60. 60.
    Wei Y et al (2008) Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47:701–706PubMedGoogle Scholar
  61. 61.
    Hansen KH et al (2008) A model for transmission of the H3K27me3 epigenetic mark. Nat Cell Biol 10:1291–1300PubMedGoogle Scholar
  62. 62.
    Fraga MF et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400PubMedGoogle Scholar
  63. 63.
    Tryndyak VP, Kovalchuk O, Pogribny IP (2006) Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 5:65–70PubMedGoogle Scholar
  64. 64.
    Pfister S et al (2008) The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer 122:1207–1213PubMedGoogle Scholar
  65. 65.
    Bosch-Presegue L, Vaquero A (2011) The dual role of sirtuins in cancer. Genes Cancer 2:648–662PubMedGoogle Scholar
  66. 66.
    Rius M, Lyko F (2011) Epigenetic cancer therapy: rationales, targets and drugs. Oncogene Dec 19. doi:10.1038/onc.2011.601Google Scholar
  67. 67.
    Pogribny IP et al (2006) Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 27:1180–1186PubMedGoogle Scholar
  68. 68.
    Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR (2010) Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 29:576–588PubMedGoogle Scholar
  69. 69.
    Das C, Lucia MS, Hansen KC, Tyler JK (2009) CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459:113–117PubMedGoogle Scholar
  70. 70.
    Williams SK, Truong D, Tyler JK (2008) Acetylation in the globular core of histone H3 on lysine-56 promotes chromatin disassembly during transcriptional activation. Proc Natl Acad Sci USA 105:9000–9005PubMedGoogle Scholar
  71. 71.
    Adkins MW, Williams SK, Linger J, Tyler JK (2007) Chromatin disassembly from the PHO5 promoter is essential for the recruitment of the general transcription machinery and coactivators. Mol Cell Biol 27:6372–6382PubMedGoogle Scholar
  72. 72.
    Meshorer E, Misteli T (2006) Chromatin in pluripotent embryonic stem cells and differentiation. Nat Rev Mol Cell Biol 7:540–546PubMedGoogle Scholar
  73. 73.
    Spivakov M, Fisher AG (2007) Epigenetic signatures of stem-cell identity. Nat Rev Genet 8:263–271PubMedGoogle Scholar
  74. 74.
    Meshorer E, Gruenbaum Y (2008) Gone with the Wnt/Notch: stem cells in laminopathies, progeria, and aging. J Cell Biol 181:9–13PubMedGoogle Scholar
  75. 75.
    Loh YH, Zhang W, Chen X, George J, Ng HH (2007) Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes Dev 21:2545–2557PubMedGoogle Scholar
  76. 76.
    Jepsen K et al (2007) SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 450:415–419PubMedGoogle Scholar
  77. 77.
    Frye M, Fisher AG, Watt FM (2007) Epidermal stem cells are defined by global histone modifications that are altered by Myc-induced differentiation. PLoS One 2:e763PubMedGoogle Scholar
  78. 78.
    Ozdag H et al (2006) Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7:90PubMedGoogle Scholar
  79. 79.
    Watanabe H et al (2008) Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 8:15PubMedGoogle Scholar
  80. 80.
    Wang JK et al (2010) The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev 24:327–332PubMedGoogle Scholar
  81. 81.
    van Haaften G et al (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41:521–523PubMedGoogle Scholar
  82. 82.
    Cherrier T et al (2009) p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene 28:3380–3389PubMedGoogle Scholar
  83. 83.
    Pollard PJ et al (2008) Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J 416:387–394PubMedGoogle Scholar
  84. 84.
    Scharer CD et al (2009) Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 69:709–717PubMedGoogle Scholar
  85. 85.
    Varambally S et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629PubMedGoogle Scholar
  86. 86.
    Kondo Y et al (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40:741–750PubMedGoogle Scholar
  87. 87.
    Min J et al (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 16:286–294PubMedGoogle Scholar
  88. 88.
    Shi Y et al (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941–953PubMedGoogle Scholar
  89. 89.
    Wissmann M et al (2007) Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9:347–353PubMedGoogle Scholar
  90. 90.
    Metzger E et al (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436–439PubMedGoogle Scholar
  91. 91.
    Metzger E et al (2010) Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 464:792–796PubMedGoogle Scholar
  92. 92.
    Shi Y (2007) Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 8:829–833PubMedGoogle Scholar
  93. 93.
    Shi L et al (2011) Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci USA 108:7541–7546PubMedGoogle Scholar
  94. 94.
    Lee MG, Wynder C, Cooch N, Shiekhattar R (2005) An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437:432–435PubMedGoogle Scholar
  95. 95.
    Shi YJ et al (2005) Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 19:857–864PubMedGoogle Scholar
  96. 96.
    Forneris F, Binda C, Vanoni MA, Battaglioli E, Mattevi A (2005) Human histone demethylase LSD1 reads the histone code. J Biol Chem 280:41360–41365PubMedGoogle Scholar
  97. 97.
    Forneris F et al (2006) A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1. J Biol Chem 281:35289–35295PubMedGoogle Scholar
  98. 98.
    Cai C et al (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20:457–471PubMedGoogle Scholar
  99. 99.
    Yosef N, Regev A (2011) Impulse control: temporal dynamics in gene transcription. Cell 144:886–896PubMedGoogle Scholar
  100. 100.
    Alenghat T et al (2008) Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456(7224):997–1000PubMedGoogle Scholar
  101. 101.
    Mohn F, Schubeler D (2009) Genetics and epigenetics: stability and plasticity during cellular differentiation. Trends Genet 25:129–136PubMedGoogle Scholar
  102. 102.
    De Santa F et al (2007) The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130:1083–1094PubMedGoogle Scholar
  103. 103.
    Cui Q et al (2007) A map of human cancer signaling. Mol Syst Biol 3:152PubMedGoogle Scholar
  104. 104.
    Dobrzynski M, Bruggeman FJ (2009) Elongation dynamics shape bursty transcription and translation. Proc Natl Acad Sci USA 106(8):2583–2588PubMedGoogle Scholar
  105. 105.
    Goldberg AD, Allis CD, Bernstein E (2007) Epigenetics: a landscape takes shape. Cell 128:635–638PubMedGoogle Scholar
  106. 106.
    Le May N et al (2010) NER factors are recruited to active promoters and facilitate chromatin modification for transcription in the absence of exogenous genotoxic attack. Mol Cell 38:54–66PubMedGoogle Scholar
  107. 107.
    Metivier R et al (2008) Cyclical DNA methylation of a transcriptionally active promoter. Nature 452:45–50PubMedGoogle Scholar
  108. 108.
    Kangaspeska S et al (2008) Transient cyclical methylation of promoter DNA. Nature 452:112–115PubMedGoogle Scholar
  109. 109.
    Wang Q et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245–256PubMedGoogle Scholar
  110. 110.
    Hu M et al (2005) Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 37:899–905PubMedGoogle Scholar
  111. 111.
    Orimo A, Weinberg RA (2006) Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5:1597–1601PubMedGoogle Scholar
  112. 112.
    Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66:4553–4557PubMedGoogle Scholar
  113. 113.
    Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33PubMedGoogle Scholar
  114. 114.
    Vita M, Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16:318–330PubMedGoogle Scholar
  115. 115.
    Fernandez PC et al (2003) Genomic targets of the human c-Myc protein. Genes Dev 17:1115–1129PubMedGoogle Scholar
  116. 116.
    Adhikary S, Eilers M (2005) Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6:635–645PubMedGoogle Scholar
  117. 117.
    Guccione E et al (2006) Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 8:764–770PubMedGoogle Scholar
  118. 118.
    Bernstein BE et al (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315–326PubMedGoogle Scholar
  119. 119.
    Secombe J, Li L, Carlos L, Eisenman RN (2007) The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. Genes Dev 21:537–551PubMedGoogle Scholar
  120. 120.
    Secombe J, Eisenman RN (2007) The function and regulation of the JARID1 family of histone H3 lysine 4 demethylases: the Myc connection. Cell Cycle 6:1324–1328PubMedGoogle Scholar
  121. 121.
    Suzuki C et al (2007) Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther 6:542–551PubMedGoogle Scholar
  122. 122.
    Ogasawara S et al (2010) Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma. Hepatol Res 40:330–336PubMedGoogle Scholar
  123. 123.
    Komiya K et al (2010) Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. J Cancer Res Clin Oncol 136:465–473PubMedGoogle Scholar
  124. 124.
    Watt FM, Frye M, Benitah SA (2008) MYC in mammalian epidermis: how can an oncogene stimulate differentiation? Nat Rev Cancer 8:234–242PubMedGoogle Scholar
  125. 125.
    Li H, Kim JH, Koh SS, Stallcup MR (2004) Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J Biol Chem 279:4212–4220PubMedGoogle Scholar
  126. 126.
    Yang X et al (2006) Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25(24):3436–3444PubMedGoogle Scholar
  127. 127.
    Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP (1997) Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15–27PubMedGoogle Scholar
  128. 128.
    Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C (2006) The insulin-like growth factor binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. J Biol Chem 281(51):39607–39619PubMedGoogle Scholar
  129. 129.
    Khanim FL et al (2004) Altered SMRT levels disrupt vitamin D(3) receptor signalling in prostate cancer cells. Oncogene 23:6712–6725PubMedGoogle Scholar
  130. 130.
    Kubota T et al (1998) 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res 58:3370–3375PubMedGoogle Scholar
  131. 131.
    Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142–153PubMedGoogle Scholar
  132. 132.
    Palmer HG et al (2004) The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 10:917–919PubMedGoogle Scholar
  133. 133.
    Saramaki A, Banwell CM, Campbell MJ, Carlberg C (2006) Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 34:543–554PubMedGoogle Scholar
  134. 134.
    Thorne J, Campbell MJ (2008) The vitamin D receptor in cancer. Proc Nutr Soc 67:115–127PubMedGoogle Scholar
  135. 135.
    Hendriksen PJ et al (2006) Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66:5012–5020PubMedGoogle Scholar
  136. 136.
    Taneja SS et al (2004) ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem 279:13944–13952PubMedGoogle Scholar
  137. 137.
    Ross-Innes CS et al (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381):389–393PubMedGoogle Scholar
  138. 138.
    Ceschin DG et al (2011) Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin. Genes Dev 25:1132–1146PubMedGoogle Scholar
  139. 139.
    Welboren WJ et al (2009) ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 28:1418–1428PubMedGoogle Scholar
  140. 140.
    Rashid SF et al (2001) Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 20:1860–1872PubMedGoogle Scholar
  141. 141.
    Abedin SA et al (2009) Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis 30(3):449–456PubMedGoogle Scholar
  142. 142.
    Lin RJ et al (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811–814PubMedGoogle Scholar
  143. 143.
    Banwell CM et al (2006) Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res 12:2004–2013PubMedGoogle Scholar
  144. 144.
    Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF (2007) Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res 5:967–980PubMedGoogle Scholar
  145. 145.
    Tomlins SA et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648PubMedGoogle Scholar
  146. 146.
    Anderson SP et al (2004) Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor {alpha}, retinoid X receptor and liver X receptor in mouse liver. Mol Pharmacol 66(6):1440–1452PubMedGoogle Scholar
  147. 147.
    Bookout AL et al (2006) Anatomical profiling of nuclear receptor expression reveals a ­hierarchical transcriptional network. Cell 126:789–799PubMedGoogle Scholar
  148. 148.
    Handschin C, Meyer UA (2005) Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 433:387–396PubMedGoogle Scholar
  149. 149.
    Xia X et al (2009) Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 106:4260–4265PubMedGoogle Scholar
  150. 150.
    Malik S, Roeder RG (2010) The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet 11:761–772PubMedGoogle Scholar
  151. 151.
    Xu J, Wu RC, O’Malley BW (2009) Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9:615–630PubMedGoogle Scholar
  152. 152.
    Taatjes DJ, Marr MT, Tjian R (2004) Regulatory diversity among metazoan co-activator complexes. Nat Rev Mol Cell Biol 5:403–410PubMedGoogle Scholar
  153. 153.
    Perissi V, Jepsen K, Glass CK, Rosenfeld MG (2010) Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet 11:109–123PubMedGoogle Scholar
  154. 154.
    Battaglia S, Maguire O, Campbell MJ (2010) Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer 126:2511–2519PubMedGoogle Scholar
  155. 155.
    Anzick SL et al (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968PubMedGoogle Scholar
  156. 156.
    Demarest SJ et al (2002) Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature 415:549–553PubMedGoogle Scholar
  157. 157.
    Zhao C et al (2003) Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 98:18–23PubMedGoogle Scholar
  158. 158.
    Doi M, Hirayama J, Sassone-Corsi P (2006) Circadian regulator CLOCK is a histone acetyltransferase. Cell 125:497–508PubMedGoogle Scholar
  159. 159.
    Esteyries S et al (2008) NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia 22:663–665PubMedGoogle Scholar
  160. 160.
    Horlein AJ et al (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397–404PubMedGoogle Scholar
  161. 161.
    Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454–457PubMedGoogle Scholar
  162. 162.
    Li J et al (2000) Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J 19:4342–4350PubMedGoogle Scholar
  163. 163.
    Yu C et al (2005) The nuclear receptor corepressors NCoR and SMRT decrease PPARgamma transcriptional activity and repress 3T3-L1 adipogenesis. J. Biol, ChemGoogle Scholar
  164. 164.
    Jepsen K, Gleiberman AS, Shi C, Simon DI, Rosenfeld MG (2008) Cooperative regulation in development by SMRT and FOXP1. Genes Dev 22:740–745PubMedGoogle Scholar
  165. 165.
    Tiefenbach J et al (2006) SUMOylation of the corepressor N-CoR modulates its capacity to repress transcription. Mol Biol Cell 17:1643–1651PubMedGoogle Scholar
  166. 166.
    Surjit M et al (2011) Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145:224–241PubMedGoogle Scholar
  167. 167.
    Heikkinen S et al (2011) Nuclear hormone 1{alpha},25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res 39(21):9181–9193PubMedGoogle Scholar
  168. 168.
    Muller-Tidow C et al (2010) Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood 116:3564–3571PubMedGoogle Scholar
  169. 169.
    Hoemme C et al (2008) Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 111:2887–2895PubMedGoogle Scholar
  170. 170.
    Minucci S et al (2000) Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 5:811–820PubMedGoogle Scholar
  171. 171.
    Girault I et al (2003) Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9:1259–1266PubMedGoogle Scholar
  172. 172.
    Zhang Z et al (2005) NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Lett 237(1):123–129PubMedGoogle Scholar
  173. 173.
    Kim JY, Son YL, Lee YC (2009) Involvement of SMRT corepressor in transcriptional ­repression by the vitamin D receptor. Mol Endocrinol 23:251–264PubMedGoogle Scholar
  174. 174.
    Chang TH, Szabo E (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8:1206–1212PubMedGoogle Scholar
  175. 175.
    Battaglia S et al (2010) Elevated NCOR1 disrupts PPAR signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis 31(9):1650–1660PubMedGoogle Scholar
  176. 176.
    Bau D et al (2011) The three-dimensional folding of the alpha-globin gene domain reveals formation of chromatin globules. Nat Struct Mol Biol 18:107–114PubMedGoogle Scholar
  177. 177.
    Li Q, Barkess G, Qian H (2006) Chromatin looping and the probability of transcription. Trends Genet 22:197–202PubMedGoogle Scholar
  178. 178.
    Eskiw CH, Rapp A, Carter DR, Cook PR (2008) RNA polymerase II activity is located on the surface of protein-rich transcription factories. J Cell Sci 121:1999–2007PubMedGoogle Scholar
  179. 179.
    Mitchell JA, Fraser P (2008) Transcription factories are nuclear subcompartments that remain in the absence of transcription. Genes Dev 22:20–25PubMedGoogle Scholar
  180. 180.
    Hu Q et al (2008) Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc Natl Acad Sci USA 105:19199–19204PubMedGoogle Scholar
  181. 181.
    Yoon HG, Chan DW, Reynolds AB, Qin J, Wong J (2003) N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol Cell 12:723–734PubMedGoogle Scholar
  182. 182.
    Yegnasubramanian S et al (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64:1975–1986PubMedGoogle Scholar
  183. 183.
    Asatiani E et al (2005) Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 65:1164–1173PubMedGoogle Scholar
  184. 184.
    Fujita N et al (2003) Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. J Biol Chem 278:24132–24138PubMedGoogle Scholar
  185. 185.
    Esteve PO et al (2006) Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 20:3089–3103PubMedGoogle Scholar
  186. 186.
    Cheng X, Blumenthal RM (2010) Coordinated chromatin control: structural and functional linkage of DNA and histone methylation. Biochemistry 49:2999–3008PubMedGoogle Scholar
  187. 187.
    Freitag M, Hickey PC, Khlafallah TK, Read ND, Selker EU (2004) HP1 is essential for DNA methylation in Neurospora. Mol Cell 13:427–434PubMedGoogle Scholar
  188. 188.
    Birney E et al (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447:799–816PubMedGoogle Scholar
  189. 189.
    Schulte JH et al (2009) Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 69:2065–2071PubMedGoogle Scholar
  190. 190.
    Graham JS, Kaye SB, Brown R (2009) The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 45:1129–1136PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Pharmacology and TherapeuticsRoswell Park Cancer InstituteBuffaloUSA
  2. 2.Institute of Biomedical Research, College of Medical and Dental SciencesUniversity of BirminghamBirminghamUK

Personalised recommendations